Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain

Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain

<br xmlns:etd="http://www.ouls.ox.ac.uk/ora/modsextensions"><strong>Background: </strong>There is a clear need to develop an objective diagnostic test for Alzheimer disease (AD). Changes in the levels of cerebrospinal fluid (CSF) tau protein and β-amyloid 42 (Aβ42) peptid...

Ausführliche Beschreibung

Bibliographische Detailangaben
Hauptverfasser:	Tapiola, T, Alafuzoff, I, Herukka, S, Parkkinen, L, Hartikainen, P, Soininen, H, Pirttilä, T
Format:	Journal article
Veröffentlicht:	American Medical Association 2009

Ähnliche Einträge

PET tau and amyloid-β burden in mild Alzheimer's disease: divergent relationship with age, cognition and cerebrospinal fluid biomarkers
von: Koychev, I, et al.
Veröffentlicht: (2017)

Regional distribution of alpha-synuclein pathology in unimpaired aging and Alzheimer disease
von: Parkkinen, L, et al.
Veröffentlicht: (2003)

Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease.
von: Fang, EF, et al.
Veröffentlicht: (2019)

Applicability of current staging/categorization of α-synuclein pathology and their clinical relevance
von: Parkkinen, L, et al.
Veröffentlicht: (2008)

The significance of α-Synuclein, Amyloid-β and Tau pathologies in Parkinson's disease progression and related dementia
von: Compta, Y, et al.
Veröffentlicht: (2013)

Systematic appraisal using immunohistochemistry of brain pathology in aged and demented subjects
von: Aho, L, et al.
Veröffentlicht: (2008)

Widespread and abundant α-synuclein pathology in a neurologically unimpaired subject
von: Parkkinen, L, et al.
Veröffentlicht: (2005)

Non-immunoglobin in cerebrospinal fluid of patients with Alzheimer's disease and cerebral amyloid angiopathy.
von: Esiri, M, et al.
Veröffentlicht: (1985)

Alpha-synuclein pathology does not predict extrapyramidal symptoms or dementia
von: Parkkinen, L, et al.
Veröffentlicht: (2004)

Correlation of Alzheimer’s Disease neuropathologic staging with amyloid and tau scintigraphic imaging biomarkers
von: Koychev, I, et al.
Veröffentlicht: (2020)

Association of lysophosphatidic acids with cerebrospinal fluid biomarkers and progression to Alzheimer's disease
von: Ahmad, S, et al.
Veröffentlicht: (2020)

Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms
von: Parkkinen, L, et al.
Veröffentlicht: (2007)

Upregulated blood miR-150-5p in alzheimer's disease dementia is associated with cognition, cerebrospinal fluid amyloid-β, and cerebral atrophy
von: Chia, Sook Yoong, et al.
Veröffentlicht: (2023)

Target tau, not amyloid, to prevent and treat Alzheimer’s disease
von: Esiri, MM
Veröffentlicht: (2020)

Differential effect of an evolving amyloid and tau pathology on brain phospholipids and bioactive lipid mediators in rat models of Alzheimer-like pathology
von: Do Carmo, S, et al.
Veröffentlicht: (2024)

Mitochondrial β-amyloid in Alzheimer's disease.
von: Borger, E, et al.
Veröffentlicht: (2011)

Unveiling amyloid-β1–42 interaction with zinc in water and mixed hexafluoroisopropanol solution in Alzheimer’s disease
von: Ghani, Nur Syafiqah Abdul, et al.
Veröffentlicht: (2017)

Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid.
von: Vafadar-Isfahani, B, et al.
Veröffentlicht: (2012)

Association of altered liver enzymes with Alzheimer disease diagnosis, cognition, neuroimaging measures, and cerebrospinal fluid biomarkers
von: Nho, K, et al.
Veröffentlicht: (2019)

Association of oxidative stress and inflammatory metabolites with Alzheimer’s disease cerebrospinal fluid biomarkers in mild cognitive impairment
von: Ahmad, S, et al.
Veröffentlicht: (2024)

Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum
von: Bos, I, et al.
Veröffentlicht: (2019)

TDP-43 interacts with amyloid-β, inhibits fibrillization, and worsens pathology in a model of Alzheimer’s disease
von: Shih, Y-H, et al.
Veröffentlicht: (2020)

Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis
von: Thompson, A, et al.
Veröffentlicht: (2018)

Cerebrospinal fluid biomarker development in amyotrophic lateral sclerosis
von: Thompson, AG
Veröffentlicht: (2018)

Folding simulation of amyloid β-peptide in alzheimer's disease.
von: Koh, Jessica Li Jian.
Veröffentlicht: (2010)

Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease.
von: Williams, S, et al.
Veröffentlicht: (2005)

Relationship of neurofibrillary pathology to cerebral amyloid angiopathy in Alzheimer's disease
von: Williams, S, et al.
Veröffentlicht: (2005)

Modelling cerebrovascular pathology and the spread of amyloid beta in Alzheimer’s disease
von: Ahern, A, et al.
Veröffentlicht: (2025)

Loss of perineuronal nets in Alzheimer's disease is not related to tau pathology
von: Baig, S, et al.
Veröffentlicht: (2004)

Practical detection of a definitive biomarker panel for Alzheimer's disease; comparisons between matched plasma and cerebrospinal fluid
von: Richens, J, et al.
Veröffentlicht: (2014)

Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's disease.
von: Chapel, H, et al.
Veröffentlicht: (1984)

Association of MAPT (tau) haplotype with the pathology of Parkinson's disease
von: Parkkinen, L, et al.
Veröffentlicht: (2013)

Aβ40 and Aβ42 amyloid fibrils exhibit distinct molecular recycling properties.
von: Sánchez, L, et al.
Veröffentlicht: (2011)

A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease
von: Kashiwaya, Y, et al.
Veröffentlicht: (2013)

A ketone ester diet exhibits anxiolytic and cognition-sparing properties, and lessens amyloid and tau pathologies in a mouse model of Alzheimer's disease.
von: Kashiwaya, Y, et al.
Veröffentlicht: (2013)

Aggregation states of Aβ1-40, Aβ1-42 and Aβp3-42 amyloid beta peptides: a SANS study
von: Festa, Giulia, et al.
Veröffentlicht: (2020)

Blood-based proteomic biomarkers of Alzheimer’s disease pathology
von: Baird, A, et al.
Veröffentlicht: (2015)

Cholinesterase activities in cerebrospinal fluid of patients with senile dementia of Alzheimer type.
von: Appleyard, M, et al.
Veröffentlicht: (1987)

Predictive ability of cerebrospinal fluid biomarkers in diagnosing and evaluating Parkinson's disease
von: Wang, Michelle J
Veröffentlicht: (2014)

The influence of insulin resistance on CSF and plasma biomarkers of Alzheimer’s pathology
von: Westwood, S, et al.
Veröffentlicht: (2017)